Trials / Completed
CompletedNCT02774278
A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)
MERIT - A Phase II Marker Identification Trial for Tarceva in Second Line NSCLC Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 264 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess potentially predictive markers of efficacy in participants with NSCLC receiving oral erlotinib (Tarceva) therapy. The anticipated time on study treatment is until disease progression, unacceptable toxicity or death.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erlotinib | Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death. |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2016-05-17
- Last updated
- 2016-08-08
- Results posted
- 2016-08-02
Locations
29 sites across 14 countries: Belgium, Bulgaria, Estonia, France, Germany, Hong Kong, Ireland, Italy, Poland, Russia, Singapore, Spain, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT02774278. Inclusion in this directory is not an endorsement.